Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

Publisher： Karger

E-ISSN： 2296-5262|28|11|582-586

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.11, 2005-10, pp. : 582-586

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 304-308

Karger

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

By  

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 554-558

Karger

Access to resources Recommend Favorite

Positive Response to Trastuzumab in a Case of HER2-Overexpressing Metastatic Gastric Cancer that Presented as Severe Thrombocytopenia

By  

Oncology Research and Treatment, Vol. 34, Iss. 11, 2011-10 ,pp. : 621-624

Karger

Access to resources Recommend Favorite